Prestige Consumer Healthcare
PBH
49.63
+0.03
+0.06%
Prestige Consumer Healthcare
US · PBH
#2733 by market cap
Listed 1970
49.63
+0.03
+0.06%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.7 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 115.49% +0.68pp
- Institutions
- 393 +10
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund101.73%
Public Company6.11%
Hedge Fund4.90%
Individual/Insider1.41%
Government Pension Fund1.25%
Private Company0.67%
Insurance Company0.36%
Family Office/Trust0.19%
Sovereign Wealth Fund0.19%
Top holders as of 2026-09-30
BlackRock
16.58% · 7.86M sh
Ariel Investments, LLC
10.27% · 4.87M sh
Vanguard Portfolio Management, LLC
5.93% · 2.81M sh
Dimensional Fund Advisors
5.59% · 2.65M sh
Fuller & Thaler Asset Management, Inc.
4.92% · 2.33M sh
State Street Global Advisors
4.66% · 2.21M sh
Vanguard Capital Management, LLC
4.53% · 2.15M sh
Brandes Investment Partners, LP
4.33% · 2.05M sh
Kayne Anderson Rudnick Investment Management, LLC
3.95% · 1.87M sh
Geode Capital Management, LLC
2.71% · 1.29M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 21 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Ronald Lombardi | Chairperson & CEO | 0.79% |
| Christine Sacco | Chief Financial Officer | 0.15% |
| John Byom | Lead Independent Director | 0.10% |
| William P'Pool | Senior Vice President | 0.09% |
| Jeffrey Zerillo | Former Officer | 0.07% |
| Sheila Hopkins | Former Independent Director | 0.06% |
| Adel Mekhail | Executive Vice President of Marketing & Sales | 0.04% |
| Mary Fritz | Former Senior Vice President of Quality & Regulatory Affairs | 0.03% |
| Dawn Zier | Independent Director | 0.03% |
| Clesteen Clark | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-03 | John Byom | Lead Independent Director | Other Acquisition | +2,981 | -- |
| 2026-08-03 | Clesteen Clark | Independent Director | Other Acquisition | +2,981 | -- |
| 2026-08-03 | Dawn Zier | Independent Director | Other Acquisition | +2,981 | -- |
| 2026-08-03 | James D'Arecca | Independent Director | Other Acquisition | +2,981 | -- |
| 2026-08-03 | John Kelly | Independent Director | Other Acquisition | +2,981 | -- |
| 2026-05-10 | Jeffrey Zerillo | Former Officer | Open Market Disposition | -351 | $52.28 |
| 2026-05-06 | Christine Sacco | Chief Financial Officer | Sale to Issuer | -991 | $54.59 |
| 2026-05-06 | Ronald Lombardi | Chairperson & CEO | Sale to Issuer | -2,543 | $54.59 |
| 2026-05-06 | Jeffrey Zerillo | Former Officer | Sale to Issuer | -351 | $54.59 |
| 2026-05-06 | Jeffrey Zerillo | Former Officer | Open Market Disposition | -305 | $54.36 |
| 2026-05-06 | Adel Mekhail | Executive Vice President of Marketing & Sales | Sale to Issuer | -487 | $54.59 |
| 2026-05-05 | Jeffrey Zerillo | Former Officer | Intent to Sell (Form 144) | -1,207 | $54.99 |
| 2026-05-04 | Christine Sacco | Chief Financial Officer | Sale to Issuer | -1,267 | $55.75 |
| 2026-05-04 | Ronald Lombardi | Chairperson & CEO | Sale to Issuer | -2,197 | $55.75 |
| 2026-05-04 | Jeffrey Zerillo | Former Officer | Sale to Issuer | -307 | $55.75 |
| 2026-05-04 | Jeffrey Zerillo | Former Officer | Private Disposition | -1,207 | $54.99 |
| 2026-05-04 | Jeffrey Zerillo | Former Officer | Open Market Disposition | -346 | $55.32 |
| 2026-05-03 | Christine Sacco | Chief Financial Officer | Sale to Issuer | -3,434 | $55.31 |
| 2026-05-03 | Christine Sacco | Chief Financial Officer | Other Acquisition | +7,008 | -- |
| 2026-05-03 | Christine Sacco | Chief Financial Officer | Other Acquisition | +11,976 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Prestige Consumer Healthcare discussion 0 comments